SLC5A2 and hydrops fetalis: Although only dapagliflozin and empagliflozin have received HF indications thus far, multiple studies offer significant supporting evidence regarding the beneficial effects of SGLT2 inhibitors when added to standard HF treatment, manifesting as early as two weeks following therapy initiation.